Login to Your Account

Other News To Note

Friday, February 17, 2012
• Cleveland BioLabs Inc., of Buffalo, N.Y., said results of the first structural and biophysical study of Toll-like receptor 5 (TLR5)/flagellin interaction help to decipher the molecular mechanisms underlying TLR5 recognition and signaling by CBLB502, an optimized derivative of bacterial flagellin and the company's candidate in development as a radiation countermeasure and a cancer therapeutic agent.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription